share_log

和誉-B(02256.HK)在2024年ACoP会议展示匹米替尼模型引导的剂量选择研究结果

Wuho-B (02256.HK) presented the dose selection study results guided by the Pimtini model at the 2024 ACoP conference.

Gelonghui Finance ·  Nov 12 15:02

On November 13, Glonghui announced that its subsidiary Shanghai Heyu Biomedical Technology Co., Ltd. ("Heyu Biomedical") presented the results of a model-guided dose selection study for its independently developed oral, highly selective, active CSF-1R small molecule inhibitor Pimitinib (ABSK021) for the treatment of tenosynovial giant cell tumor ("TGCT") at the 2024 USA Quantitative Pharmacology Conference ("2024 ACoP Conference"). The published research integrated information on drug metabolism, safety, and efficacy to guide model-informed dose selection. The results support a recommended dose of 50mg QD for Pimitinib's global development and treatment of TGCT.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment